Evidence map›Paper›PMID 38529712›Full record

ArticleMicrobial biotechnology2024

Engineering the carbon and redox metabolism of Paenibacillus polymyxa for efficient isobutanol production.

Meliawati Meliawati, Daniel C Volke, Pablo I Nikel, Jochen Schmid

Open access · goldAbstract read
In one paragraph

Article in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. CRISPR-Cas9-driven genome editing inFrontiers in microbiology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Meliawati MeliawatiInstitute of Molecular Microbiology and Biotechnology, University of Münster, Münster, Germany.ORCID 0000-0003-2440-7000
Daniel C VolkeThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.
Pablo I NikelThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark.ORCID 0000-0002-9313-7481
Jochen SchmidInstitute of Molecular Microbiology and Biotechnology, University of Münster, Münster, Germany.ORCID 0000-0003-2557-5532
Novo Nordisk Foundation · DKUniversity of Münster · DE

Funding

Bundesministerium für Bildung und Forschung 031B0855AErasmus+ KA131Open Access Publication Fund of the Universität Münster
6 · The paper itself

Abstract

Paenibacillus polymyxa is a non-pathogenic, Gram-positive bacterium endowed with a rich and versatile metabolism. However interesting, this bacterium has been seldom used for bioproduction thus far. In this study, we engineered P. polymyxa for isobutanol production, a relevant bulk chemical and next-generation biofuel. A CRISPR-Cas9-based genome editing tool facilitated the chromosomal integration of a synthetic operon to establish isobutanol production. The 2,3-butanediol biosynthesis pathway, leading to the main fermentation product of P. polymyxa, was eliminated. A mutant strain harbouring the synthetic isobutanol operon (kdcA from Lactococcus lactis, and the native ilvC, ilvD and adh genes) produced 1 g L

Indexed as

ButanolsPaenibacillusPaenibacillus polymyxaCarbonMetabolic EngineeringNADPOxidation-ReductionButanolsCarbonisobutyl alcoholNADP

Identifiers

PMID38529712
PMCPMC10964175
OpenAlexW4393203480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.